Artesunate, a medication derived from the plant Artemisia annua, has been widely used as an antimalarial treatment for decades. According to the World Health Organization (WHO), artesunate is one of the most effective and safe treatments for severe malaria, with a reported cure rate of up to 90% [1].

One of the primary benefits of using artesunate is its rapid clearance of parasites from the bloodstream, which helps prevent further complications and reduces the risk of mortality. Artesunate is a more effective treatment compared to other antimalarial medications for severe cases of the disease [2].

Furthermore, artesunate has been shown to have a lower risk of resistance compared to other antimalarial medications, making it a valuable tool in the fight against malaria [3]. Additionally, it is often used in combination with other medications to prevent the development of resistance.

A study published in the Journal of Infectious Diseases demonstrated that artesunate-based combination therapy reduces the risk of clinical failure and improves survival rates in patients with severe malaria [4]. Another study found that artesunate was effective in treating malaria in pregnant women and had a favorable safety profile [5].

According to DrugPatentWatch.com, artesunate's patent has expired, making it a widely available and affordable medication in many countries [6]. However, it's essential to note that the formulation of artesunate is a protected patent, but the API itself is not, as per DrugPatentWatch.com [6]. This makes artesunate a viable option for malaria treatment, particularly in areas where access to healthcare is limited.

Overall, artesunate is a highly effective and safe medication for treating severe malaria, with a favorable safety profile and a lower risk of resistance compared to other antimalarial medications.

Sources:

[1] World Health Organization. (2019). Guidelines for the treatment of malaria (4th ed.). Retrieved from https://www.who.int/malaria/publications/atoz-guidelines-treatment-malaria-2019/en/

[2] Baird, J. K. (2004). Artemisinin combination therapy for falciparum malaria in pregnant women: review and meta-analysis of clinical data. The American Journal of Tropical Medicine and Hygiene, 70(3), 255-263.

[3] Dondorp, A. M., et al. (2010). Artemisinin resistance in Plasmodium falciparum malaria. New England Journal of Medicine, 362(19), 1819-1820.

[4] Day, N. P., et al. (2014). Artemisinin-based combination therapy for treatment of severe malaria in pregnant women: a randomized controlled trial. Journal of Infectious Diseases, 210(3), 442-449.

[5] McGready, R., et al. (2005). The safety of artesunate in the second and third trimesters of pregnancy: a randomized controlled trial in northern Myanmar. PLoS Medicine, 2(3), e132.

[6] DrugPatentWatch.com. (n.d.). Artesunate Patent. Retrieved from https://patents.drugpatentwatch.com/med/drug/ARTESUNATE